ReviewFrontiers in endocrinology2026
Quantitative pancreatic MRI in diabetes mellitus: current advances and future directions.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, the diagnosis and monitoring of diabetes mellitus (DM) primarily rely on clinical symptoms, blood glucose measurements, and laboratory blood tests. With the continuous advancement of medical imaging, magnetic resonance imaging (MRI) is increasingly being applied to the study of diabetes and its associated complications. Given that the pancreas plays a pivotal role in the pathogenesis and progression of DM, quantitative MRI techniques have emerged as powerful tools; they provide not only fundamental structural information but also visualize the pathophysiological alterations of the pancreas throughout the disease course. This literature review suggests that quantitative pancreatic MRI holds great promise as a novel, non-invasive biomarker for evaluating diabetic pathophysiology, facilitating early diagnosis, and monitoring therapeutic efficacy. Advancing this field further, the integration of artificial intelligence and radiomics offers powerful tools for automated high-throughput mining of these datasets, though its clinical translation remains preliminary. Current implementation gaps-most notably the critical need for multi-center external validation and standardized models-must be recognized before these deep imaging phenotypes can be reliably utilized in clinical settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.